Health TrialsbyHealthPanel

Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer

ConditionsUterine Cervical NeoplasmsChemoradiotherapyAdjuvant Chemotherapy
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorFourth Affiliated Hospital of Guangxi Medical University

About this trial

This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma

FIGO stage IB3, IIA2, IIB-IVA patients in 2018

Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment

Aged 18-75 years

Disqualifiers

Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment

Patients who have received neoadjuvant chemotherapy and surgery

Patients with cognitive impairment

Patients with any distant metastases

Trial design

Design model

Parallel

Treatments tested in this trial

  • paclitaxel combined with platinum

    Drug

    Adjuvant chemotherapy with paclitaxel combined with platinum

Treatment groups

108 Participants
are divided into 2 treatment groups
Group A: concurrent chemoradiotherapy combined with adjuvant chemotherapyExperimental treatment 1 intervention
Group B: concurrent chemoradiotherapyOther 1 intervention

Trial outcomes

Primary outcomes

1

PFS

progression-free survival

Time frame
Refers to the time from randomization to the first occurrence of disease progression or death from any cause，whichever came first, assessed up to 1000 months

Secondary outcomes

1

OS

Overall survival

Time frame
Refers to the time from randomization to death from any cause, assessed up to 1000 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fourth Affiliated Hospital of Guangxi Medical University

Lead sponsor

Source ClinicalTrials.gov
Apply now